Which do you feel plays a more important role in the health of your patients with diabetes? 1) Nutrition 2) Exercise 3) Both

Your patient has been taking metformin, glipizide, and a daily basal insulin dose (.85 U/kg/day). While his fasting glucose levels are on target, he has not yet been able to reach his individualized glycemic target of A1C<7%. In your discussion with him about the addition of a prandial insulin dose to his regimen, you compare and contrast his options. Compared to basal insulin alone, premixed insulins: A. tend to lower A1c to a larger degree. B. are associated with less weight gain. C. cause less hypoglycemia. D. are a good option for people with irregular meal schedules. Follow the link to see the right answer.

Dr. Sam Engel is the Associate Vice President, Cardiometabolic and Women’s Health at Merck Research Laboratories. He graduated from New York University School of Medicine. Prior to joining Merck’s team, he was a Clinical Professor at Albert Einstein College of Medicine.

Samuel Engel discusses Merck's VERTIS clinical trial program and recent ertugliflozin research including the VERTIS SITA study and the VERTIS MET study,

In this Exclusive Interview, Dr. Samuel Engel talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California about the results of studies related to ertugliflozin.

In part 1 of this Exclusive Interview, Dr. Samuel Engel talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California about the results of the new SGLT-2, ertugliflozin.

In part 2 of this Exclusive Interview, Dr. Samuel Engel explains the effects of ertugliflozin on typical biometrics in a conversation with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California.

In part 3 of this Exclusive Interview, Dr. Samuel Engel talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California about the cardiovascular study portion of the ertugliflozin trial.

In part 4 of this Exclusive Interview, Dr. Samuel Engel talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California about looking at the impact of DPP-4s on hypoglycemia.

Our publisher got a chance to sit down with Dr Aaron Vinik at a recent AACE meeting. For those of you who have been following our publication for the past 18 years, you have seen Dr. Vinik’s name repeatedly. He was one of the first “legends in diabetes” to have …